Spots Global Cancer Trial Database for Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Official Title: Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Study ID: NCT00031980
Interventions
Study Description
Brief Summary: RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.
Detailed Description: OBJECTIVES: * Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine. OUTLINE: This is a multicenter study. Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 4 months for 1 year and then every 6 months for 9 years. PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Roswell Park Cancer Institute, Buffalo, New York, United States
Contact Details
Name: Maria R. Baer, MD
Affiliation: University of Maryland Greenebaum Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
